SCHEMBL2979486

SCHEMBL2979486

COC(=O)c1ccc(Cl)c(NC(=O)c2ccc3ncccc3c2)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.70
HTT P42858 1/20 0.70
HDAC1 Q13547 1/20 0.58
HDAC2 Q92769 1/20 0.58
PLK1 P53350 1/20 0.56
ALDH1A1 P00352 4/20 0.54
NPC1 O15118 3/20 0.53
RAB9A P51151 3/20 0.53
KDM4E B2RXH2 1/20 0.52
DOT1L Q8TEK3 1/20 0.51
MEN1 O00255 2/20 0.51
LMNA P02545 2/20 0.51
POLB P06746 2/20 0.51
KMT2A Q03164 2/20 0.51
MAPT P10636 2/20 0.51
GAA P10253 1/20 0.51
DYRK1A Q13627 1/20 0.51
DYRK1B Q9Y463 1/20 0.51
HPGD P15428 1/20 0.50
ABCB1 P08183 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2976951 0.87 HDAC1 (0.61) ALOX15HTTHDAC1HDAC2PLK1
SCHEMBL27509830 0.87 HDAC1 (0.61) ALOX15HTTHDAC1HDAC2PLK1
Hydrochloric Acid SCHEMBL2974700 0.86 HDAC1 (0.60) ALOX15HTTHDAC1HDAC2PLK1
SCHEMBL30718649 0.84 ALOX15 (1.00) ALOX15HTTHDAC1HDAC2PLK1
SCHEMBL265015 0.84 ALOX15 (1.00) ALOX15HTTHDAC1HDAC2PLK1
SCHEMBL27928930 0.83 ALOX15 (0.97) ALOX15HTTHDAC1HDAC2PLK1
SCHEMBL2963586 0.81 CSF1R (0.57) HTTHDAC1HDAC2PLK1ALDH1A1
SCHEMBL5897023 0.81 PABPC1 (0.72) HTTHDAC1HDAC2PLK1ALDH1A1
Quinoline SCHEMBL28071393 0.80 ALOX15 (0.91) ALOX15HTTHDAC1HDAC2PLK1
SCHEMBL1057121 0.79 ALOX15 (0.62) ALOX15HTTHDAC1HDAC2PLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7772432-B2 Amidobenzamide derivatives which are useful as cytokine inhibitors ASTRAZENECA AB (SE) 2010-08-10 US disclosed
CN-1243724-C Amide derivatives which are useful as cell factor inhibitors ASTRA ZENECA LTD (SE) 2006-03-01 CN disclosed
US-20050038081-A1 Amidobenzamide derivatives which are useful as cytokine inhibitors ASTRAZENECA 2005-02-17 US disclosed
US-6821965-B1 IMPORTANT IN DISEASE OR MEDICAL CONDITIONS SUCH AS INFLAMMATION AND IMMUNOREGULATION ASTERZENECA AB (SE) 2004-11-23 US disclosed
EP-1102743-B1 AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS ASTRAZENECA AB (SE) 2002-07-24 EP disclosed
CN-1330631-A Amide derivatives which are useful as cell factor inhibitors ASTRA ZENECA LTD (SE) 2002-01-09 CN disclosed
EP-1102743-A1 AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS AstraZeneca AB (SE) 2001-05-30 EP disclosed
WO-2000007980-A1 AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS ASTRAZENECA AB (SE) 2000-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038081-A1 Amidobenzamide derivatives which are useful as cytokine inhibitors IL6, IL6ST, IL2 ALOX15 1267/4885HTT 2817/4885HDAC1 139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.